切换至 "中华医学电子期刊资源库"

中华结直肠疾病电子杂志 ›› 2017, Vol. 06 ›› Issue (06) : 442 -446. doi: 10.3877/cma.j.issn.2095-3224.2017.06.001

所属专题: 文献

指南与共识

结直肠癌术中腹腔化疗专家意见(2017版)
中国医师协会结直肠肿瘤专业委员会1   
  1. 1. 100021 北京,国家癌症中心/中国医学科学院北京协和医学院肿瘤医院结直肠外科
  • 收稿日期:2017-08-27 出版日期:2017-12-25
  • 基金资助:
    国家自然科学基金面上项目(No.81572930); 中国医学科学院肿瘤医院学科带头人奖励基金(No.RC2016003); 国家重点研发计划精准医学研究专项(No.2016YFC0905300); 中国医学科学院医学与健康科技创新工程项目(No.2016-I2M-1-001)

Chinese expert opinion on intraoperative chemotherapy for colorectal cancer (2017 edition)

Colorectal Cancer Committee of Chinese Medical Doctor Association1   

  • Received:2017-08-27 Published:2017-12-25
  • About author:
    Corresponding author: Wang Xishan, Email:
引用本文:

中国医师协会结直肠肿瘤专业委员会. 结直肠癌术中腹腔化疗专家意见(2017版)[J]. 中华结直肠疾病电子杂志, 2017, 06(06): 442-446.

Colorectal Cancer Committee of Chinese Medical Doctor Association. Chinese expert opinion on intraoperative chemotherapy for colorectal cancer (2017 edition)[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2017, 06(06): 442-446.

结直肠癌是我国最常见的恶性肿瘤之一,其发病率居高不下,腹腔种植转移作为常见转移方式,是治疗失败的常见原因之一。腹腔化疗将化疗药物注入腹腔,直接作用于腹腔内种植和脱落的癌细胞,维持腹腔内较高的有效药物浓度,延长作用时间,是治疗和预防结直肠癌腹腔种植转移的重要方法。腹腔化疗的方案种类繁多,用量及浓度也差别较大,尚无统一标准规范。为了规范结直肠癌术中腹腔化疗适应证及禁忌证的选择、规范腹腔灌注化疗药物的用法用量及术后监测指标等,中国医师协会结直肠肿瘤专业委员会组织国内相关领域权威专家,制定《结直肠癌术中腹腔化疗专家意见》,旨在规范结直肠癌术中腹腔化疗方法,提高我国结直肠肿瘤的整体诊治水平,延长结直肠癌患者生存时间并改善生活质量。

Colorectal cancer is one of the most common malignancies in China. The incidence of colorectal cancer is high, and intraperitoneal implantation is one of the common causes of treatment failure. Intraperitoneal chemotherapy, which directly injects the chemotherapeutic drugs into the abdominal cavity to inhibit the intraperitoneal implantation and shedding of cancer cells, improve the intraperitoneal effective drug concentration, and prolong the effect of time, is one of the important methods of treatment and prevention of colorectal cancer intraperitoneal transplantation. Because of many various programs, there is no uniform standard in the amount and concentration of drugs. Therefore, in order to regulate the colorectal cancer intraoperative chemotherapy indications and contraindications, regulate the usage of intraperitoneal injection of chemotherapy drugs and the monitoring indicators, the relevant experts from Colorectal Cancer Committee of Chinese Medical Doctor Association developed ″Colorectal cancer intraoperative chemotherapy expert advice″. It aimed at regulate the method of colorectal cancer intraperitoneal chemotherapy, improve the overall prevention of colorectal peritoneal metastasis in China, extend the survival time of patients with colorectal cancer and improve the quality of life.

1
Chen WZR,Baade PD,Zhang S, et al. Cancer Statistics in China, 2015 [J]. CA Cancer J Clin, 2016, 66 (2): 115-132.
2
Cunningham D,Atkin W,Lenz HJ, et al. Colorectal cancer [J]. Lancet, 2010, 375 (9719): 1030-1047.
3
al JDFSLCe. Peritoneal careinomatosis from colorectal cancer [J]. Br J Surg, 2002, 89 (12): 1545-1550.
4
何振华,张森,宋现青. 结直肠癌腹膜种植转移的相关因素分析 [J]. 中国肿瘤临床, 2013, 40 (2): 107-110.
5
Kim MS CC,Yoo S,Cho C, et al. Stereotactic body radiation therapy in patients with pelvic recurrence from rectal carcinoma [J]. Jpn J Clin Oncol, 2008, 38 (10): 695-700.
6
Fisher B GN,Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases [J]. Cancer Res, 1983, 43: 1488-1492.
7
Elias D,Glehen O,Pocard M, et al. A comparative study of complete cytoreduetive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and no pseudomyxoma appendix [J]. Ann Surg, 2010, 251 (5): 896-901.
8
Sugarbaker PH. Carcinomatosis from gastrointestinal cancer [J]. Ann Med, 2004, 36 (1): 9-22.
9
Seymour MT,Trigonis I,Finan PJ, et al. A feasibility, pharmacokinetic and frequency-escalation trial of intraperitoneal chemotherapy in high risk gastrointestinal tract cancer [J]. Eur J Surg Oncol, 2008, 34 (4): 403-409.
10
姜福全,王强,蔡清萍. 氟尿嘧啶腹腔内缓释化疗的家兔门静脉血药浓度测定 [J]. 外科理论与实践, 2006, 11(6): 524-527.
11
Xue Bai,Bo Yu,Junfeng, et al. Effects of lobaplatin and oxaliplatin on biological behavior of colorectal carcinoma cell line [J]. Chinese-German Journal of Clinical Oncology, 2010, 9 (1): 36-39.
12
王琳,谢贤和,陈俊民. 含洛铂联合化疗方案治疗晚期消化道恶性肿瘤Meta分析 [J]. 山东医药, 2013, 53(34): 48-50.
13
Laboratories A. Lobaplatin:D 19466 [J]. Drugs RD, 2003, 4(6): 369-372.
14
Bleiberg H,Vandebroek A,Deleu I, et al. A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer [J]. Acta Gastroenterol Belg, 2012, 75 (1): 14-21.
15
Kim R PG,Shridhar R,Hoffe SE, et al. Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma [J]. Radiother Oncol, 2016, 118 (2): 382-386.
16
Archer S,Gray B. IntraperitoneaI 5-fIuorouraciI infusion for treatment of both peritoneaI and Iiver micrometastases [J]. Surgery, 1992, 108(3): 502-507.
17
Vaillant JC NB,Deuffic S,Arnaud JP, et al. Adjuvant intraperitoneal 5-fluorouracil in high-risk colon cancer: A multicenter phase III trial [J]. Ann Surg, 2000, 231 (4): 449-456.
18
Yasui H1 MK,Shimada Y,Tsuji A, et al. A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study [J]. J Cancer Res Clin Oncol, 2015, 14 (1): 153-160.
19
HiIIan K,NoroIinger B,BaIIet F, et aI. The heaIing of coIonic anastomoses after earIy intraperitoneaI chemotherapy: an experimentaI study in rats [J]. J Surg Res, 1988, 44 (2): 166-171.
20
肖军,金钦文,覃字周. 结直肠癌根治术中植入缓释氟尿嘧啶安全性及疗效荟萃分析 [J]. 中华普通外科杂志, 2011, 26(4): 358-359.
21
Zhao P,Ding Z,Tang L, et al. Preliminary investigation of intraperitoneal raltitrexed in patients with gastric cancer [J]. World J Surg Oncol, 2014, 12 (1): 1-7.
[1] 康夏, 田浩, 钱进, 高源, 缪洪明, 齐晓伟. 骨织素抑制破骨细胞分化改善肿瘤骨转移中骨溶解的机制研究[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 329-339.
[2] 代莉, 邓恢伟, 郭华静, 黄芙蓉. 术中持续输注艾司氯胺酮对腹腔镜结直肠癌手术患者术后睡眠质量的影响[J]. 中华普通外科学文献(电子版), 2023, 17(06): 408-412.
[3] 王得晨, 杨康, 杨自杰, 归明彬, 屈莲平, 张小凤, 高峰. 结直肠癌微卫星稳定状态和程序性死亡、吲哚胺2,3-双加氧酶关系的研究进展[J]. 中华普通外科学文献(电子版), 2023, 17(06): 462-465.
[4] 付佳, 肖海敏, 武曦, 冯涛, 师帅. 年龄校正查尔森合并症指数对腹腔镜结直肠癌围手术期并发症的预测价值[J]. 中华普通外科学文献(电子版), 2023, 17(05): 336-341.
[5] 薛永婷, 高峰, 王雅楠, 屈莲平. 溶瘤病毒治疗在结直肠癌中的应用[J]. 中华普通外科学文献(电子版), 2023, 17(05): 380-384.
[6] 唐旭, 韩冰, 刘威, 陈茹星. 结直肠癌根治术后隐匿性肝转移危险因素分析及预测模型构建[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 16-20.
[7] 张生军, 赵阿静, 李守博, 郝祥宏, 刘敏丽. 高糖通过HGF/c-met通路促进结直肠癌侵袭和迁移的实验研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 21-24.
[8] 李婷, 张琳. 血清脂肪酸代谢物及维生素D水平与结直肠癌发生的关系研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 661-665.
[9] 常剑, 邱峰, 毛郁琪. 摄食抑制因子-1与腹腔镜结直肠癌根治术后肝转移的关系分析[J]. 中华普外科手术学杂志(电子版), 2023, 17(05): 502-505.
[10] 王晓燕, 肖佑, 肖戈, 王真权. 老年结直肠癌肺转移CT特征及高危因素研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(05): 506-509.
[11] 关旭, 王锡山. 基于外科与免疫视角思考结直肠癌区域淋巴结处理的功与过[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 448-452.
[12] 顾睿祈, 方洪生, 蔡国响. 循环肿瘤DNA检测在结直肠癌诊治中的应用与进展[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 453-459.
[13] 倪文凯, 齐翀, 许小丹, 周燮程, 殷庆章, 蔡元坤. 结直肠癌患者术后发生延迟性肠麻痹的影响因素分析[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 484-489.
[14] 范小彧, 孙司正, 鄂一民, 喻春钊. 梗阻性左半结肠癌不同手术治疗方案的选择应用[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 500-504.
[15] 孙昕, 程海波, 沈卫星. 基于全转录组学探讨仙连解毒方治疗Ⅲ期结直肠癌患者的疗效机制[J]. 中华消化病与影像杂志(电子版), 2023, 13(05): 277-283.
阅读次数
全文


摘要